ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO080

Beneficial Effect of Statin on Preventing Contrast-Induced AKI in Patients with Renal Insufficiency: A Meta-Analysis

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Cho, Ajin, Hallym university Kangnam Sacred Heart Hospital, Seoul, Korea (the Republic of)
  • Noh, Jung-woo, Chun & Cho's Medical Clinic & Dialysis Center, Seoul, Korea (the Republic of)
  • Kim, Juhee, Department of Internal Medicine-Nephrology, Gangnam Sacred Heart Hospital, Korea, Republic of, Seoul, Korea (the Republic of)

Renal insufficiency is an important predictor of contrast-induced acute kidney injury (CI-AKI). We performed a meta-analysis to examine the effects of short-term statin therapy on the incidence of CI-AKI, particularly in patients with renal insufficiency.


A systematic search was conducted to retrieve randomized controlled trials (RCTs) that investigated the impact of statin pretreatment before administration of contrast media on the development of CI-AKI in patients with mild to moderate renal insufficiency. The primary outcome was development of CI-AKI. The secondary outcome was the incidence of AKI requiring hemodialysis.


Data analysis from eight RCTs, which included a total of 2313 subjects in the statin-treated group and 2322 in the control group, showed that statin pretreatment was associated with significant reduction of the risk of CI-AKI (Relative Risk (RR) = 0.59; 95% Confidential Interval (CI) 0.44 to 0.79; p = 0.0003, I2 = 0%). A beneficial effect of statin on preventing CI-AKI was consistent, regardless of the dose of statin and use of N-acetylcysteine. The incidence of hemodialysis was low after contrast administration in the statin-treated group, but the reduction was not significant (RR = 0.28; 95% CI 0.05 to 1.70; p = 0.17, I2 = 0%). In subgroup analysis based on baseline estimated glomerular filtration rate (eGFR), patients with baseline eGFR < 60 ml/min/1.73 m2 (RR = 0.63; 95% CI 0.41 to 0.98; p = 0.04, I2 = 0%) and 30 < eGFR < 90 ml/min/1.73 m2 (RR = 0.56; 95% CI 0.39 to 0.82; p = 0.003, I2 = 0%) showed significant reduction of risk of CI-AKI.


Statin pretreatment is effective at preventing CI-AKI and should be considered in patients with pre-existing renal insufficiency.